Featured content
Why reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
ArticleThe next gene-editing breakthrough may start with the donor template
The editing machinery gets much of the attention in genome editing, but it’s the donor DNA template that can determine whether an edit works. Long synthetic ssDNA could offer researchers another option.
ArticleScientists are already using AI agents. Most of what they learn goes unpublished.
Dr Raminderpal Singh speaks to Dr Srijit Seal about how AI agents are changing computational drug discovery, the impact on scientists’ daily work and why valuable findings remain unpublished.
ArticleWhat will it take to trust human-relevant models in drug discovery?
Could organ-on-a-chip technology help identify drug failures before clinical trials? Jim Corbett of Emulate discusses the evidence needed to make human-relevant models reliable tools in drug discovery.
News
Newsp53 activation boosts T-cell potency against solid tumours
UCLA researchers have shown that transiently activating the tumour suppressor protein p53 using an investigational MDM2 inhibitor can reduce exhaustion in engineered T cells and significantly improve their ability to kill melanoma cells in vitro.
NewsSMVT brain transporter protein opens new drug delivery route
Researchers have identified a transporter protein that could enable creatine derivatives and other therapeutic compounds to cross the blood-brain barrier, with potential implications for treating Creatine Transporter Deficiency Syndrome and other neurological disorders.
NewsBispecific antibody targets regulatory T cells to enhance tumour immunity
A bispecific antibody targeting CCR8 and CD3 has demonstrated the ability to deplete immunosuppressive regulatory T cells and slow tumour growth across multiple cancer models.
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
From our partners
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Opinion and interviews
How multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Cracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Cracking cell dynamics with single-cell proteomics and CRISPR
What it really takes to turn cancer discoveries into new therapies
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
